

TUMOUR	TRIAL	Line	KEY POINTS - TRIAL/AGENT: PHASE 1	PI	SC
Melanoma	EVX-02-001	Adj	Ph 1b/2, EVX-02 and anti-PD-1 After Complete Resection of Stage IIIb/c or Stage IV Melanoma in pts at High Risk for Recurrence	MA	KB
Solid Tumour	AMG256		Ph 1, AMG 256 in Patients with Advanced Solid Tumors	SF	PM
Solid Tumour	BGB-A317-A445-101		Ph 1, Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combo With the Anti-PD-1 Monoclonal Antibody Tislelizumab in pts with Advanced Solid Tumors	SF	JK
Solid Tumour	V941-001		Ph 1, mRNA-5671/V941 as a Monotherapy and in Combo with Pembro in pts with KRAS Mutant Advanced or Metastatic NSCLC, Colorectal Cancer or Pancreatic Adenocarcinoma	SF	LS
Solid Tumour	AKESO - AK104-101	2 nd	Ph1A, dose esc of AK104-101 (bispecific PD1 and CTLA4 inhibitor) for advanced solid. No prior IO.	SF	LC
Solid Tumour	AMBRX ARX788-1711	2 nd	Her2+ gastric/breast only. Failed std therapy. Prior HER2 directed therapy accepted. Local HER2 testing accepted.	SF	PM
Solid Tumour	C-Stone Anti PDI	2 nd	Ph1, CS1003 (anti-PD1) in advanced solid tumour. Failed std therapy. No prior IO. – Part 1 completed Part 2 combo of PD1 + Regorafenib in dose escalation Colorectal only still recruiting.	DD	JK
Solid Tumour	MYPHISMO – 17-010	2 nd	Ph1, Trial of a Combined Immune Modulatory approach using TetMYB Vaccine & anti-PD1 antibody in pys with Advanced Solid Cancer including Colorectal or Adenoid Cystic Carcinoma	ES	JK
Solid Tumour	TIGIT (BGB-900-105)	2 nd	Ph 1/1b, Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combo with Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) in Pts with PDL1 positive >1% 1st line NSCLC, 1st line SCLC (any), or checkpoint experienced later line NSCLC.	SF	IP
Solid Tumour	BEIGENE BGB-900-103	3 rd	Ph1b, Preliminary Antitumor Activity of Sitravatinib in Combo With Tislelizumab in Pts With naïve NSCLC- Squamous or non-squamous, PDL1 positive	DD	IP
Solid Tumour	AKESO – AK112-01	2 nd +	Ph 1a/1b, Dose-escalation & Dose-expansion Study of AK112 in Subjects with Ovarian & Advanced Solid Tumors	SF	JK
Solid tumour	CORVUS CPI-006-001:	2 nd +	Ph1/1B, Anti-Cd73 Antibody, Cpi-006, Single Agent, In Combo With Cpi-444, & In Combo With Pembro In pts with Advanced Cancers	DP	PM
Solid Tumour	HARBOUR BIOMED	2 nd +	Ph1, Anti-tumour Activity of HBM4003 in pts with Advanced Solid tumours	DD	PM
Solid Tumour	Maxinovel	2 nd +	Ph I study of MAX-10181 in patients with solid tumors	DD	PM
TUMOUR	TRIAL	Line	TRIAL/AGENT: PHASE 2/3	PI	SC
Breast	Kyoto Palbo	NEO	Ph 3, Neoadjuvant HRT plus Palbo V's HRT plus Placebo in pts with Operable, Hormone Sensitive & HER2-Negative Primary Breast Cancer	MW	LR
Breast	ALEXANDRA	ADJ	Ph 3, Atezolizumab in combination with Adjuvant Anthracycline/Taxane-based Chemo V's Chemo alone in Operable TNBC	MH	LR
Breast	Checkmate 7FL	NEO/ADJ	Ph 3, Nivolumab V's Placebo in Combo With Neoadjuvant Chemo & Adjuvant Endocrine Therapy in pts With High-risk, ER+HER2- Primary BC	KW	EW
Breast	PATINA Her2+	1 st	Ph 3, Palbociclib + std therapy vs. std therapy in ER/PR+, Her2+ MBC, 1st line	MW	EW
Breast	AZTEC: Breast TNBC	1 st / 2 nd	Ph 2, comparing single fraction or multi-fraction SABR with Atezo for advanced TNBC, Note: mandatory biopsies pre C1, C3 and progression, frequent imaging	MW	EW
Breast	CAPTURE	2 nd	Ph 2, Alpelisib & Fulvesrant V's Capecitabine in ER+ & HER2 - advanced breast cancer patients with PIK3CA mutant circulating DNA	MW	LR
Breast	BRCA P	N/A	Ph 3, Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation	MH	HW
Endometrial	LEAP-001	1 st	Ph 3 Pembro (MK-3475) + Lenvatinib (E7080/MK-7902) V's Chemo 1st Line treatment for Advanced or Recurrent Endometrial Carcinoma	SF	KG
Ovarian	I Prime	NEO	Ph 2, Durvalumab + Tremelimumab with standard chemo in pts with ovarian, fallopian or peritoneal cancers	KW	EW
Ovarian	ENGOT (Keylynk -001)	Neo + Adj	Ph 3, Chemo +/- Pembro followed by maintenance with Olaparib or Placebo, 1st Line treatment for BRCA non-mutated Advanced Epithelial Ovarian Cancer	SF	KG
Ovarian	ICON 9	2 nd	Ph 3 Olaparib +/- Cediranib in relapsed platinum-sensitive ovarian carcinoma following a response to Platinum-based Chemotherapy	KW	LR
Ovarian	Mirasol	2 nd	Ph 3, Mirvetuximab Soravtansine v's investigator's choice chemo in pts with platinum-resistant high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers whose tumors express a high level of folate receptor alpha expression	SF	EW
Ovarian	Precise	2 nd	Ph 3 Pamiparib in ABCB1 fusion +ve, BRCA reversion –ve high grade serous ovarian cancer or carcinosarcoma with BRCA1/2 mutations who have progressed on PARP inhibitors or chemotherapy	KW	HW
Cervical	Akeso104-201	2 nd	Ph 2 AK104 (bispecific PD1 and CTLA4 inhibitor) for advanced cervical SCC or adenosquamous carcinoma	KW	HW

PH 1
 Breast
 Gynaecology
 Genitourinary (GU)
 Gastrointestinal (GI)
 Lung
 Head & Neck
 Other

TUMOUR	TRIAL	Line	TRIAL/AGENT: PHASE 2/3	PI	SC
Bladder	Keynote 905	NEO	Ph 3 Cystectomy plus Perioperative Pembro v's Cystectomy alone in Cisplatin-ineligible pts with Muscle invasive Bladder Cancer	DP	LG
Bladder	Keynote 992	1 st	Ph 3, Pembrolizumab (MK-3475) in Combo with hemoradiotherapy (CRT) v's CRT Alone in pts with Muscle-invasive Bladder Cancer (MIBC)	EL	SK
Prostate	Keynote 991	1 st	Ph 3, Enzalutamide + ADT + Pembrolizumab/Placebo in participants with mHSPC	DP	LG
Prostate	AMG 509	1 st	Ph 1, AMG 509 in Subjects with Metastatic Castration-resistant Prostate Cancer	DP	LG
Prostate	Keynote 641	2 nd	Ph 3, Enzalutamide + Pembrolizumab/placebo in Participants with mCRPC. (Prior abiraterone cohort still recruiting)	DP	SK
Prostate	Checkmate 650	1 st	Ph 2, Nivolumab + Ipilimumab, Ipilimumab, or Cabazitaxel in patients with mCRPC	DP	LG
Prostate	EH prostate biology	N/A	Studies of prostate cancer biology	EK	NN
Renal	Keypad	2 nd	Ph 2, 2nd line , Denosumab + Pembro in ccRCC	DP	SK
Renal	UNICAB	2 nd	Ph 2, Cabozantinib, Post/Non-suitable immunotherapy	DP	LD
Biliary Tract	MS-0055	1 st	Ph 2/3, Gemcitabine + Cisplatin With or Without M7824 (bintrafusp alfa) as First-line Treatment of Biliary Tract Cancer	ES	NB
Cholangiocarcinoma	PROOF	1 st	Ph 3, Oral Infigratinib v's Gemcitabine + Cisplatin in pts with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations	MH	JG
Colorectal	ASCOLT	ADJ	Ph 3, Adjuvant Aspirin vs Placebo in secondary prevention CRC (Dukes C or high risk Dukes B)	AS	NB
Colorectal	Monarcc	1 st	Ph 2, Panitumumab vs Panitumumab + 5-FU, as 1st line therapy, mCRC (RASwt/BRAFwt)	ES	NB
Colorectal	Checkmate 8HW	1 st	Ph 3, of Nivo alone, Nivo in + Ipilimumab, or an Investigator's Choice Chemo in pts with MSI-H or dMMR metastatic colorectal	AS	JG
Colorectal	Lynk 003	2 nd	Ph 3 Olaparib Alone or +/- Bevacizumab compared to Bevacizumab + 5-FU in pts with unresectable or Metastatic Colorectal Cancer who have not Pprogressed Following First-line Induction of FOLFOX With Bevacizumab	AS	JG
Rectal	AveRec	NEO	Ph 2, Neoadjuvant Avelumab + std therapy, locally advanced rectal	ES	JG
Rectal	Dynamic Rectal	ADJ	Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Locally Advanced Rectal Cancer	MH	JG
Gastric or GEJ	Keynote 811	1 st	Ph 2, 1st line treatment Pembro/Placebo + Trastuzumab + Chemotherapy in HER2 Positive Advanced Gastric or GEJ Adenocarcinoma	ES	NB
Gastric or GEJ	Spotlight	1 st	Ph 3, 1st line treatment for Claudin (CLDN)18.2-Positive, HER2-Negative , Locally Advanced Unresectable or Metastatic Gastric or GEJ Adenocarcinoma IMAB362 + FOLFOX6 v's Placebo + FOLFOX6	AS	NB
Gastric/OES	INTEGRATE II	3 rd & 4 th	Ph 3, Regorafenib vs Placebo, in 3L/4L in met/locally recurrent GOJ/Stomach (adeno or undiff)	AS	NB
Neuroendocrine	ASPEN	1 st	Pancreas ASPEN Asymp/non-func, pNET ≤ 2 cm, prospective evaluation	ES	NB
Neuroendocrine	NET SANGUIS		The Potential Role Of Circulating DNA In The Management Of Pancreatic Neuroendocrine Tumours	ES	NB
Pancreatic	NAPOLI 3	1 st	Ph 3, irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin v's nab-paclitaxel + gemcitabine in pts not previously received chemo for metastatic adenocarcinoma of the pancreas	ES	JG
Pancreas	Medimmune D6070	1 st Line	Ph 1b/2 Oleclumab (MEDI9447) +/- Durvalumab in Combo with Chemo in pts with Metastatic Pancreatic Ductal Adenocarcinoma	SF	JG
MESO	TRIZELL	2 nd & 3 rd	Ph 3, Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combo with Celecoxib & Gemcitabine in Pts with Malignant Pleural Mesothelioma	PB	LM
NSCLC	Keychain 006	1 st	Ph 3, Pembro in combo with Pemetrexed/Platinum (Carboplatin or Cisplatin) followed by Pembro & maintenance Olaparib vs maintenance Pemetrexed in the 1st Line treatment of metastatic nonsquamous NSCLC	PB	LT
NSCLC	Keychain 008	1 st	Ph 3, Pembro in Combo with Carboplatin/Paclitaxel or Nab-paclitaxel Followed by Pembro +/- Maintenance Olaparib in the 1st line Treatment of Metastatic Squamous NSCLC	PB	LT
NSCLC	LIBRETTO-431	1 st	Ph 3, Comparing LOXO-292 to Platinum-Based & Pemetrexed Therapy +/- Pembro as Initial Treatment of Advanced or Metastatic RET Fusion-Positive NSCLC	MA	TH

PH 1
 Breast
 Gynaecology
 Genitourinary (GU)
 Gastrointestinal (GI)
 Lung
 Head & Neck
 Other

TUMOUR	TRIAL	Line	TRIAL/AGENT: PHASE 2/3	PI	SC
NSCLC	<u>OUTRUN</u>	1 st & 2 nd	Ph 2, Osimertinib +/- SABR for EGFR mutated NSCLC with Brain Metastases (1L or after progression EGFR TKI with T790M mutation)	MA	TH
NSCLC	<u>AMGEN 510</u>	2 nd	Ph 3, AMG 510 V's Docetaxel for the Treatment of previously treated Locally Advanced and unresectable or Metastatic NSCLC with KRAS p.G12C Mutation	PB	LT
NSCLC	<u>ILLUMINATE</u>	2 nd	Ph 2, Durvalumab + Tremelimumab with chemo following progression on EGFR Tyrosine Kinase Inhibitors	PB	TH
NSCLC	<u>SKYSCRAPER</u>	2 nd	PH I/III, atezo + Tiragolumab v's durvalumab in pts with unresectable stage 3 NSCLC - not progressed after concurrent Platinum-based chemoradiation	AM	TH
NSCLC	AMGEN Bio	N/A	A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer	PB	LM
HNSCC	<u>MK-145-002</u>	1 st	Ph 2 Metastatic or Unresectable, Recurrent HNSCC to Evaluate Intratumoral MK-1454 in Combo with IV Pembro vs IV Pembro Monotherapy	AM	LM
R/M HNSCC	<u>Leap 009</u>	2 ND	Ph 2, lenvatinib (E7080/MK-7902) + pembro (MK-3475) v's SOC chemo & lenvatinib monotherapy in pts with (R/M HNSCC) after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors)	AM	LM
Cutaneous	<u>CERPASS</u>	N/A	Ph 2, Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma	MA	LT
Melanoma	<u>STOPGAP</u>	ALL	Ph 3 study of duration of anti-PD-1 therapy in metastatic melanoma	MA	TH

PH 1
 Breast
 Gynaecology
 Genitourinary (GU)
 Gastrointestinal (GI)
 Lung
 Head & Neck
 Other

Stream Contact Numbers

Phase 1 – 0474 769 510

GI – 0436 386 758

Breast & Gynaecological – 0491 299 561

Lung/Head & Neck – 0417 607 416

GU – 0436 387 664